Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: A critical review and meta analysis

Expert Review of Anticancer Therapy

Volumn 15, Issue 1, 2014, Pages 129-141

  Abdel Rahman, Omar ^a   Fouad, Mona ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

hand foot skin reaction; meta analysis; mucocutaneous toxicities; skin rash; stomatitis; sunitinib; tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; DOCETAXEL; ERLOTINIB; PACLITAXEL; PAZOPANIB; PLACEBO; PREDNISONE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CASTRATION RESISTANT PROSTATE CANCER; CONTINUOUS INFUSION; DRUG APPROVAL; GASTROINTESTINAL STROMAL TUMOR; HAIR DISCOLORATION; HAND FOOT SYNDROME; HUMAN; INCIDENCE; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER CELL CARCINOMA; LUNG CANCER; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; NON SMALL CELL LUNG CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK ASSESSMENT; RISK FACTOR; SKIN DISCOLORATION; SOLID TUMOR; STOMATITIS; SYSTEMATIC REVIEW; TREATMENT DURATION; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); DRUG ERUPTION; HAND-FOOT SYNDROME; MUCOSA INFLAMMATION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG ERUPTIONS; HAND-FOOT SYNDROME; HUMANS; INDOLES; MUCOSITIS; PYRROLES;

EID: 84919821838     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.985660     Document Type: Article

References (41)

1. Oudard S, Beuselinck B, Decoene J, et al. Sunitinib for the treatment of metastatic renal cell carcinoma. Cancer Treat Rev 2011;37(3):178-84
2. Theou-Anton N, Faivre S, Dreyer C, et al. Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer. Drug Saf 2009;32(9):717-34
3. Sunitinib drug monograph. Cancer Care Ontario drug formulary. Available from: www.cancercare.on.ca/toolbox/drugs/drugformulary
4. Demetri GD, Garrett CR, Schöffski P, et al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res 2012; 18(11):3170-9
5. Abdel-Rahman O. Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside. J Egypt NatlCanc Inst 2013;25(4):165-71
6. Abdel-Rahman O, Fouad M. Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2014. [Epub ahead of print]
7. Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and Meta analysis. Expert Rev Anticancer Ther 2014;1-8. [Epub ahead of print]
8. Fabbrocini G, Cameli N, Romano MC, et al. Chemotherapy and skin reactions. J Exp Clin Cancer Res 2012;31:50
9. Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib; an updated systematic review and meta analysis. Expert Rev Anticancer Ther 2014; 14(6):751-60
10. Billemont B, Barete S, Meric JB, et al. Skin toxicity of sunitinib: Prospective analysis in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol In ASCO Annual Meeting Proceedings 2008; 26(15 Suppl):16146
11. Pfizer pharma, sutent prescribing information. Available from: www.pfizer.ca/fr/our-products/products/monograph/147
12. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviewsand Meta-Analyses: The PRISMA Statement. J Clin Epidemiol 2009;62(10):1006-12
13. National cancer institute, common toxicity criteria. Available from: http://ctep.cancer. gov/protocoldevelopment/electronic-applications/docs/ctcaev3.pdf [Last accessed on 18 Dec 2013]
14. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3): 177-88
16. Yoshiji H, Kuriyama S, Yoshii J, et al. halting the interaction between vascular endothelial growthfactor and its receptors attenuates liver carcinogenesis in mice. Hepatology 2004;39:1517-24
17. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2):115-24
18. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369(8):722-31
19. Huynh H, Ngo VC, Choo SP, et al. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma. Curr Cancer DrugTargets 2009; 9(6):738-47
20. Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with Sunitinib, axitinib, cediranib or regorafenib; an updated systematic review and comparative meta analysis. Crit Rev Oncol Hematol 2014; Epub ahead of print
21. Abdel-Rahman O, Fouad M. Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis. Expert Rev Anticancer Ther 2014;14(9):1063-73
22. Abdel-Rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. Crit Rev Oncol Hematol. 2014; Epub ahead of print
23. Huggins RH, Kuzel TM, Anderson RT, et al. Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib: impact on quality of life (QoL). In J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):16122
24. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009;10(8):757-63
25. Lankheet N, Mallo H, Haanen JB, et al. Quantification of sunitinib in sweat secretion. J Clin Oncol In ASCO Annual Meeting Proceedings 2010;28(15 Suppl): e15094
26. Erdem L, Giovannetti E, Leon LG. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. Curr Top Med Chem 2012;12(15):1649-59
27. Chen D, Gordon J, Ibrahim O, et al. Management of dermatologic toxicities associated with epidermal growth factor inhibitors (EGFRIs) and multikinase inhibitors (MKIs). J Clin Oncol (Meeting Abstracts) 2011;29(15 Suppl):e19624
28. Poprach I, Pavlik T, Melichar B, et al. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann Oncol 2012;23(12):3137-43
29. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4): 378-90
30. Chu D, Lacouture ME, Weiner E, et al. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a metaanalysis. Clin Genitourin Cancer 2009;7(1):11-19
31. Négrier S, Gravis G, Pérol D, et al. Temsirolimus and bevacizumab, or sunitinib, or interferonalfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 2011;12(7): 673-80
32. Socinski MA, Scappaticci FA, Samant M, et al. Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol 2010;5(3):354-60
33. Wildiers H, Fontaine C, Vuylsteke P, et al. Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010; 123(2):463-9
34. Crown JP, Diéras V, Staroslawska E, et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 2013;31(23):2870-8
35. Scagliotti GV, Krzakowski M, Szczesna A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 2012;30(17): 2070-8
36. Cheng AL, Kang YK, Lin DY, et al. Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: results of a Randomized Phase III Trial. J Clin Oncol 2013;31(32):406775
37. Bergh J, Bondarenko IM, Lichinitser MR, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 2012;30(9):921-9
38. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):501-13
39. Groen HJ, Socinski MA, Grossi F, et al. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). Ann Oncol 2013;24(9):2382-9
40. Barrios CH, Liu MC, Lee SC, et al. Phase III randomized trial of sunitinib versus capecitabine inpatients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010;121(1):121-31
41. Michaelson MD, Oudard S, Ou YC, et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol 2014;32(2):76-82